Ranking Profile - Graybug Vision Inc

Introduction

CalciMedica Inc (CalciMedica), formerly Graybug Vision Inc, is a clinical-stage pharmaceutical company that develops next-generation products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Its pipeline portfolio comprise GB-102, GB-601, GB-701, GB-501 and GB-401.The company’s lead candidate includes GB-102, a clinical-stage depot formulation of sunitinib malatcontains, which is a single small molecule compound that blocks multiple pathogenic angiogenesis pathways included in choroidal neovascularization that causes neovascular or wet age-related macular degeneration. It develops products for the treatment of major eye diseases that includes glaucoma, retinal vein occlusion, diabetic macular edema, corneal graft rejection, and others. CalciMedica's proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye. The company operates through its research center located in Baltimore, Maryland, the US. CalciMedica is headquartered in Redwood City, California, the US.